PubRank

Francis Giles

Author PubWeight™ 195.39‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2006 8.38
2 Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 8.26
3 Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005 7.83
4 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007 5.54
5 Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005 4.06
6 Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006 4.04
7 Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005 4.00
8 Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004 3.76
9 Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood 2002 3.46
10 Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood 2007 3.29
11 Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007 3.27
12 Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood 2007 2.91
13 Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004 2.78
14 High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2003 2.75
15 Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. Blood 2005 2.44
16 Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006 2.36
17 BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther 2008 2.31
18 Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006 2.22
19 The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer 2007 2.21
20 New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006 2.14
21 Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 2003 2.06
22 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2007 2.05
23 Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006 1.97
24 Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007 1.95
25 Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood 2003 1.87
26 Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood 2006 1.82
27 A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res 2008 1.77
28 Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003 1.76
29 Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood 2003 1.72
30 Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res 2004 1.68
31 Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 2003 1.67
32 AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005 1.61
33 Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004 1.49
34 Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res 2008 1.45
35 A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 2007 1.42
36 Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003 1.42
37 Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha. Blood 2004 1.41
38 Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia. Leuk Res 2003 1.40
39 Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 2007 1.37
40 Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer 2006 1.36
41 Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood 2009 1.36
42 Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells. Blood 2006 1.36
43 Biphenotypic acute leukaemia: a case series. Br J Haematol 2007 1.36
44 Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). Blood 2004 1.33
45 Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies. Cancer 2004 1.24
46 Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2002 1.24
47 Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008 1.23
48 The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents. Target Oncol 2009 1.21
49 Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006 1.19
50 Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2002 1.16
51 Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome. Br J Haematol 2004 1.14
52 Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia? Hematol Oncol 2006 1.11
53 Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res 2007 1.10
54 Cdc7 kinase - a new target for drug development. Eur J Cancer 2010 1.09
55 Higher detection rate of JAK2 mutation using plasma. Blood 2008 1.09
56 The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004 1.07
57 Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center. Blood 2005 1.06
58 Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003 1.06
59 Troxacitabine in leukemia. Hematology 2006 1.06
60 The Pim kinases: new targets for drug development. Curr Drug Targets 2011 1.06
61 Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood 2003 1.05
62 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003 1.04
63 Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica 2007 1.02
64 Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma 2007 1.02
65 Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer 2007 1.00
66 Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations. Cancer 2008 0.99
67 New agents in acute myeloid leukemia and other myeloid disorders. Cancer 2004 0.97
68 Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002 0.96
69 An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation. Leuk Res 2007 0.96
70 New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol 2007 0.95
71 A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer 2006 0.94
72 Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience. Cancer 2005 0.94
73 A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 2006 0.93
74 Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res 2009 0.93
75 Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia. Cancer 2004 0.92
76 Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res 2003 0.92
77 A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leuk Lymphoma 2007 0.92
78 PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study. Cancer 2007 0.92
79 Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer 2006 0.91
80 Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 2003 0.91
81 Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase. Cancer 2003 0.90
82 Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer 2009 0.90
83 Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer 2004 0.89
84 Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 2006 0.89
85 AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer 2005 0.88
86 Recent advances in the diagnosis and therapy of Richter's syndrome. Med Oncol 2007 0.88
87 Advances in the therapy of chronic idiopathic myelofibrosis. Oncologist 2006 0.88
88 Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 2003 0.87
89 Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience. Am J Hematol 2004 0.87
90 Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy. Cancer 2004 0.86
91 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer 2005 0.86
92 Targeting sarcomas: novel biological agents and future perspectives. Curr Drug Targets 2009 0.86
93 Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies. Leuk Res 2004 0.86
94 Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003 0.86
95 Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 2003 0.85
96 Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 2003 0.85
97 Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opin Ther Targets 2008 0.85
98 Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling. PLoS One 2011 0.85
99 Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma 2007 0.85
100 Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 2009 0.85
101 Current status of therapy for chronic myeloid leukemia: a review of drug development. Future Oncol 2008 0.85
102 Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer 2008 0.85
103 Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol 2005 0.83
104 Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004 0.83
105 Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. Eur J Haematol 2003 0.82
106 A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2003 0.82
107 Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 2006 0.81
108 Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer 2003 0.81
109 Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 2007 0.81
110 A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia. Leuk Res 2006 0.81
111 Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res 2004 0.81
112 Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer 2007 0.80
113 Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? Expert Opin Pharmacother 2013 0.80
114 C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res 2004 0.80
115 Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease. J Gastroenterol Hepatol 2011 0.80
116 Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue. Clin Cancer Res 2006 0.80
117 Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies. Cancer 2004 0.80
118 Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia. Leuk Res 2012 0.79
119 Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J 2007 0.79
120 JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms. PLoS One 2010 0.79
121 The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy. Leuk Lymphoma 2005 0.78
122 Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer 2007 0.78
123 Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia. Cancer 2006 0.78
124 T-cell prolymphocytic leukemia: a single-institution experience. Clin Lymphoma Myeloma 2005 0.78
125 Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol 2002 0.78
126 Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy. Cancer 2005 0.78
127 Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer 2005 0.77
128 Hairy cell leukemia. Med Oncol 2007 0.77
129 Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica 2002 0.77
130 Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells. Cancer Sci 2006 0.77
131 Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes. Leuk Lymphoma 2003 0.76
132 Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003 0.76
133 A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia. Invest New Drugs 2010 0.76
134 Investigational strategies in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004 0.76
135 A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes. Haematologica 2002 0.75
136 Circulating CD33 and its clinical value in acute leukemia. Exp Hematol 2010 0.75
137 Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies. Cancer 2008 0.75
138 Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges. Clin Lymphoma Myeloma 2007 0.75
139 Gemtuzumab ozogamicin: a component of induction therapy in AML? Leuk Res 2005 0.75
140 Phase I study of oral topotecan in hematological malignancies. Clin Cancer Res 2003 0.75
141 Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML. Leuk Res 2003 0.75
142 New agents in chronic myelogenous leukemia. J Natl Compr Canc Netw 2003 0.75
143 Myelodysplastic syndrome: from morphology to biology. Curr Hematol Rep 2004 0.75
144 Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. Leuk Lymphoma 2009 0.75
145 A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma. Leuk Lymphoma 2007 0.75